Hologic raises annual profit forecast on diagnostic and surgical demand

Hologic (HOLX.O) raised its fiscal 2025 adjusted profit forecast to $4.23-$4.26 per share and narrowed its revenue outlook to $4.08 billion-$4.09 billion, citing robust demand for its molecular diagnostic and surgical products. The medical equipment maker's shares rose 3.5% in extended trading, reflecting investor optimism following its Q3 adjusted profit of $1.08 per share and revenue of $1.02 billion, both exceeding analyst estimates, despite a temporary weakness in its breast health segment expected to recover in Q4.

Analysis

Hologic (HOLX) has issued a stronger outlook, raising its fiscal 2025 adjusted earnings per share forecast to a range of $4.23 to $4.26, which is notably above the analyst consensus of $4.18. This upgrade is supported by a third-quarter performance that surpassed expectations, with adjusted EPS of $1.08 versus an estimated $1.05 and revenue of $1.02 billion slightly ahead of the $1.01 billion consensus. The positive revision is primarily driven by sustained demand for its molecular diagnostic and surgical products. However, this strength is partially offset by a notable 5.1% revenue decline in its breast health segment during the quarter. Management has signaled confidence that this is a temporary issue, projecting an acceleration in overall growth for the fourth quarter, contingent on a recovery in that specific unit. The market has responded positively to this guidance, with shares climbing 3.5% in extended trading, reflecting investor optimism in the company's ability to execute on its forecast.

Key Decisions for Investors

• Investors should view the raised profit guidance and Q3 earnings beat as a strong positive signal, reinforcing the company's operational strength in its core diagnostics and surgical divisions.
• The key risk to monitor is the performance of the breast health segment; its projected recovery in Q4 is critical for achieving management's accelerated growth targets and validating the current outlook.
• Given the positive after-hours stock movement, consideration should be given to whether the improved guidance is fully priced in, or if potential for further upside exists pending confirmation of the breast health unit's turnaround.